Health experts hail Ebola breakthrough

Preliminary test results for vaccine show positive

©Charlie Bibby

Celgene hesitation costs it almost $7bn

Receptos deal could have been made for much less two years ago

US dollar pushes Sanofi profit higher

Sales rise 16%, buoyed by exchange rates and Genzyme biotech unit

AstraZeneca beats earnings expectations

Pharma group points to strong pipeline of cancer drugs

Papaver somniferum. Seed pod of Opium Poppy.

Pharmaceuticals: Prescribing pain

Increasing abuse of painkillers in the US is putting the industry under pressure to make the drugs tamper-proof

Wanted: Recreational drug users — will pay

Race is on to develop new ‘abuse-deterrent’ opioid painkillers

2016 earnings growth promise by ‘new GSK’

Leading UK drugmaker highlights R & D progress as sales advance 7%

Lone Star seeks to score at Wembley

Texan private equity group snaps up Quintain Estates for £700m

Pfizer chief has ‘courage’ to pursue deals

Speculation over $17bn cash pile has grown as rivals consolidate

Rachel Brough, Senior Scientific Officer at the Institute of Cancer Research works in a laboratory, testing new drugs, at the ICR. Photographed for UK News
©Charlie Bibby

Clinical trial data should be made public

Drug companies and regulators are adopting transparency too slowly

Hikma boosts US generics with Roxane buy

Jordanian group to pay a mixture of cash and shares to Boehringer

Allergan paves way for new mega deal

Chief hints at ‘transformational’ purchase after generics sale

Pharma M&A: portfolio theory

Even after a $40bn deal, the pharma sector remains unsettled

Upbeat Reckitt raises growth forecasts

Dettol disinfectant maker reports 10% profit rise as outlook for Europe and North America stabilises

Mylan plunges after Teva abandons bid

Shares drop as Israeli group pursues rival Allergan deal

Allergan on the move with $41bn Teva deal

Israeli group’s deal with Botox maker ends pursuit of Mylan

Bioven seeks IPO to market Cuban drug

Cuba’s life science sector stands to benefit from country’s improved relations with US

Companies diary: July 27 — July 31

Diary commentary from FT reporters

Teva closes in on Allergan’s generics unit

Deal likely to end Israeli company’s pursuit of Mylan

GlaxoSmithKline: dose of reality

Mosquirix approval is good but pharma group needs more than that

EDITOR’S CHOICE

Special report

insulin vials ©Jacob Ehrbahn Combating Diabetes

Special report

An elderly man uses a magnifier to see the descriptions on a pack of medicine at a pharmacy in Dandong, Liaoning province March 30, 2011 ©Jacky Chen/Reuter Health: Emerging Markets

COMPANIES NEWS ON TWITTER

More FT Twitter accounts
SHARE THIS QUOTE